ProNAi Relaunched as Sierra Oncology to Advance DDR-Based Cancer Drugs

VANCOUVER, Jan. 9, 2017 /CNW/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, today announced it has changed its corporate name to Sierra Oncology, Inc. and that its shares will trade on the NASDAQ under the symbol ‘SRRA’, effective on January 10th. The company’s new name reflects its evolution into an oncology focused company advancing an emerging pipeline of promising therapies that target the DNA Damage Response (DDR) network.

Read more:  ProNAi Relaunched as Sierra Oncology to Advance DDR-Based Cancer Drugs